{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:18:53Z","timestamp":1791425933006,"version":"4.3.3"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T00:00:00Z","timestamp":1478131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["079838"],"award-info":[{"award-number":["079838"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["100476"],"award-info":[{"award-number":["100476"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["098051"],"award-info":[{"award-number":["098051"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"DOI":"10.1371\/journal.ppat.1005971","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T13:47:25Z","timestamp":1478180845000},"page":"e1005971","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":83,"title":["Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in Leishmania"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8810-5605","authenticated-orcid":true,"given":"Susan","family":"Wyllie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6834-549X","authenticated-orcid":true,"given":"Adam J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-1994","authenticated-orcid":true,"given":"Suzanne","family":"Norval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8374-5590","authenticated-orcid":true,"given":"Bernardo J.","family":"Foth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9581-0377","authenticated-orcid":true,"given":"Matthew","family":"Berriman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5134-0329","authenticated-orcid":true,"given":"Alan H.","family":"Fairlamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,11,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"J Alvar","year":"2012","journal-title":"PLoS One"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0035-9203(03)80047-0","article-title":"M\u00e9decins Sans Fronti\u00e8res interventions against kala-azar in the Sudan, 1989\u20132003","volume":"97","author":"K Ritmeijer","year":"2003","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug Resistance in Leishmaniasis","volume":"19","author":"SL Croft","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trstmh.2006.02.005","article-title":"Unresponsiveness to AmBisome in some Sudanese patients with kala-azar","volume":"101","author":"M Mueller","year":"2007","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1517\/14728210903153862","article-title":"Developments in the treatment of visceral leishmaniasis","volume":"14","author":"ML den Boer","year":"2009","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African <italic>Trypanosoma brucei gambiense<\/italic> trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"G Priotto","year":"2009","journal-title":"Lancet"},{"issue":"119re1","key":"ref7","article-title":"The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis","volume":"4","author":"S Wyllie","year":"2012","journal-title":"Sci Transl Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e1870","DOI":"10.1371\/journal.pntd.0001870","article-title":"Fexinidazole: a potential new drug candidate for Chagas disease","volume":"6","author":"MT Bahia","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejps.2014.09.006","article-title":"<italic>In vitro<\/italic> metabolism, disposition, preclinical pharmacokinetics and prediction of human pharmacokinetics of DNDI-VL-2098, a potential oral treatment for Visceral Leishmaniasis","volume":"65","author":"R Mukkavilli","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"13088","DOI":"10.1074\/jbc.M111.230847","article-title":"Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites","volume":"286","author":"BS Hall","year":"2011","journal-title":"J Biol Chem"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1128\/AAC.00332-10","article-title":"Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis","volume":"54","author":"AY Sokolova","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1128\/AAC.01788-12","article-title":"Assessing the essentiality of <italic>Leishmania donovani<\/italic> nitroreductase and its role in nitro drug activation","volume":"57","author":"S Wyllie","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1073\/pnas.0711014105","article-title":"A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes","volume":"105","author":"SR Wilkinson","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e09744","DOI":"10.7554\/eLife.09744","article-title":"The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis","volume":"5","author":"S Patterson","year":"2016","journal-title":"eLife"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1128\/AAC.00722-13","article-title":"The <italic>R<\/italic> enantiomer of the anti-tubercular drug PA-824 as a potential oral treatment for visceral leishmaniasis","volume":"57","author":"S Patterson","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jac\/dkv376","article-title":"Nitroheterocyclic drug resistance mechanisms in <italic>Trypanosoma brucei<\/italic>","volume":"71","author":"S Wyllie","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/35016103","article-title":"A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis","volume":"405","author":"CK Stover","year":"2000","journal-title":"Nature"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1124\/dmd.115.064527","article-title":"Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: importance of albumin metabolism in vivo","volume":"43","author":"K Sasahara","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"ref19","first-page":"9","article-title":"Flavoprotein Protocols","author":"A Aliverti","year":"1999"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e923","DOI":"10.1371\/journal.pntd.0000923","article-title":"Fexinidazole\u2014a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness","volume":"4","author":"E Torreele","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature10771","article-title":"High-throughput decoding of antitrypanosomal drug efficacy and resistance","volume":"482","author":"S Alsford","year":"2012","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1128\/AAC.05135-11","article-title":"Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation","volume":"56","author":"BS Hall","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.str.2011.11.001","article-title":"Structure of Ddn, the deazaflavin-dependent nitroreductase from <italic>Mycobacterium tuberculosis<\/italic> Involved in bioreductive activation of PA-824","volume":"20","author":"SE Cellitti","year":"2012","journal-title":"Structure"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1742-4658.2011.08404.x","article-title":"Substrate specificity of the deazaflavin-dependent nitroreductase from <italic>Mycobacterium tuberculosis<\/italic> responsible for the bioreductive activation of bicyclic nitroimidazoles","volume":"279","author":"M Gurumurthy","year":"2012","journal-title":"FEBS J"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1126\/science.1164571","article-title":"PA-824 kills nonreplicating <italic>Mycobacterium tuberculosis<\/italic> by intracellular NO release","volume":"322","author":"R Singh","year":"2008","journal-title":"Science"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1476-5381.2010.01040.x","article-title":"Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in <italic>Mycobacteria<\/italic> and a subcellular fraction of human liver","volume":"162","author":"M Dogra","year":"2011","journal-title":"Br J Pharmacol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4161\/cib.2.3.7926","article-title":"The mechanism of action of PA-824: Novel insights from transcriptional profiling","volume":"2","author":"U Manjunatha","year":"2009","journal-title":"Commun Integr Biol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cbpa.2014.01.019","article-title":"New developments in &apos;ene&apos;-reductase catalysed biological hydrogenations","volume":"19","author":"HS Toogood","year":"2014","journal-title":"Curr Opin Chem Biol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cbpa.2007.02.025","article-title":"Asymmetric bioreduction of activated C = C bonds using enoate reductases from the old yellow enzyme family","volume":"11","author":"R Stuermer","year":"2007","journal-title":"Curr Opin Chem Biol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1099\/00221287-148-6-1607","article-title":"&apos;New uses for an Old Enzyme&apos;\u2014the Old Yellow Enzyme family of flavoenzymes","volume":"148","author":"RE Williams","year":"2002","journal-title":"Microbiology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1084\/jem.20020885","article-title":"A key role for old yellow enzyme in the metabolism of drugs by <italic>Trypanosoma cruzi<\/italic>","volume":"196","author":"BK Kubata","year":"2002","journal-title":"J Exp Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0166-6851(03)00142-7","article-title":"An <italic>in vitro<\/italic> system for developmental and genetic studies of <italic>Leishmania donovani<\/italic> phosphoglycans","volume":"130","author":"S Goyard","year":"2003","journal-title":"Mol Biochem Parasitol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/jlcr.1914","article-title":"Synthesis of <sup>2<\/sup>H- and <sup>14<\/sup>C-labeled fexinidazole and its primary metabolites labeled with <sup>2<\/sup>H","volume":"54","author":"E Fontana","year":"2011","journal-title":"J Label Compd Radiopharm"},{"key":"ref34","unstructured":"Winkelmann E. and Raether W., inventors; Hoechst Aktiengesellschaft, assignees (16-8-1977) 1-Methyl-2-(phenyl-oxymethyl)-5-nitro-imidazoles and process for their manufacture. United States patent application 4,042,705."},{"key":"ref35","doi-asserted-by":"crossref","first-page":"7854","DOI":"10.1021\/jm060957y","article-title":"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-<italic>b<\/italic>]oxazoles","volume":"49","author":"H Sasaki","year":"2006","journal-title":"J Med Chem"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0223-5234(89)90034-2","article-title":"Nitroimidazoles XXI. 2,3-Dihydro-6-nitroimidazo[2,1-B]oxazoles with antitubercular Activity","volume":"24","author":"K Nagarajan","year":"1989","journal-title":"Eur J Med Chem"},{"key":"ref37","first-page":"e36619","article-title":"Comparative SILAC proteomic analysis of <italic>Trypanosoma brucei<\/italic> bloodstream and procyclic lifecycle stages","volume":"7","author":"MD Urbaniak","year":"2012","journal-title":"J Parasitol Res"},{"key":"ref38","first-page":"289","article-title":"Cultivation and in vitro cloning of procyclic culture forms of <italic>Trypanosoma brucei<\/italic> in a semi-defined medium","volume":"36","author":"R Brun","year":"1979","journal-title":"Acta Trop"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1021\/pr101065j","article-title":"Andromeda: a peptide search engine integrated into the MaxQuant environment","volume":"10","author":"J Cox","year":"2011","journal-title":"J Proteome Res"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/nbt.1511","article-title":"MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification","volume":"26","author":"J Cox","year":"2008","journal-title":"Nat Biotechnol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1021\/pr401209w","article-title":"High-confidence glycosome proteome for procyclic form <italic>Trypanosoma brucei<\/italic> by epitope-tag organelle enrichment and SILAC proteomics","volume":"13","author":"ML Guther","year":"2014","journal-title":"J Proteome Res"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1042\/BST0330983","article-title":"The myo-inositol-1-phosphate synthase gene is essential in <italic>Trypanosoma brucei<\/italic>","volume":"33","author":"K Martin","year":"2005","journal-title":"Biochem Soc Trans"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nmeth.1311","article-title":"Amplification-free Illumina sequencing-library preparation facilitates improved mapping and assembly of (G+C)-biased genomes","volume":"6","author":"I Kozarewa","year":"2009","journal-title":"Nat Methods"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1101\/gr.123430.111","article-title":"Whole genome sequencing of multiple <italic>Leishmania donovani<\/italic> clinical isolates provides insights into population structure and mechanisms of drug resistance","volume":"21","author":"T Downing","year":"2011","journal-title":"Genome Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The Sequence Alignment\/Map format and SAMtools","volume":"25","author":"H Li","year":"2009","journal-title":"Bioinformatics"}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.ppat.1005971","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T03:49:31Z","timestamp":1568519371000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1005971"}},"subtitle":[],"editor":[{"given":"Stephen M.","family":"Beverley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,11,3]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1005971","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,3]]}}}